Related Experiment Video
Updated: Jan 12, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
49.2K
Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review
Crystal Banh1,2, Aleksandar Sic1,3, Nebojsa Nick Knezevic4,5,6
1Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, 60657, USA.
CNS Drugs
|November 3, 2025
Summary
New non-opioid pain relievers targeting specific sodium channels (Nav1.7 and Nav1.8) show promise. Suzetrigine (VX-548) is the first FDA-approved Nav1.8 inhibitor, offering hope for safer, nonaddictive pain management.
Area of Science:
- Pain research
- Neuropharmacology
- Drug discovery
Background:
- Chronic and neuropathic pain are difficult to treat with current drugs like opioids and NSAIDs.
- Voltage-gated sodium channels Nav1.7 and Nav1.8 are key targets for pain relief due to their role in pain signaling.
- Limited efficacy and safety concerns hinder conventional pain therapies.
Purpose of the Study:
- To review novel sodium channel inhibitors for pain management.
- To highlight suzetrigine (VX-548) and other investigational agents.
- To discuss challenges and future strategies in developing nonaddictive analgesics.
Main Methods:
- Review of clinical development of sodium channel inhibitors.
- Focus on Nav1.8 inhibitors like suzetrigine (VX-548).
- Analysis of investigational agents including ralfinamide, OLP-1002, LTGO-33, and HBW-004285.
Main Results:
- Suzetrigine (VX-548) is the first FDA-approved Nav1.8 inhibitor for acute pain.
- Despite early challenges, ongoing trials show promise for a new class of analgesics.
- Emerging strategies are addressing issues like selectivity and on-target side effects.
Conclusions:
- Novel sodium channel inhibitors offer a potential alternative to opioids and NSAIDs.
- Advances in structural biology and precision medicine are crucial for developing effective pain treatments.
- Future pain therapies aim to be safer, more effective, and nonaddictive.
Related Concept Videos
01:25Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
01:26Voltage-gated Ion Channels
10.3K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
10.3K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
01:24Non-gated Ion Channels
8.0K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
8.0K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
01:44Nociception
33.0K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
33.0K